glipizide has been researched along with Chronic Kidney Diseases in 2 studies
Glipizide: An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.
glipizide : An N-sulfonylurea that is glyburide in which the (5-chloro-2-methoxybenzoyl group is replaced by a (5-methylpyrazin-2-yl)carbonyl group. An oral hypoglycemic agent, it is used in the treatment of type 2 diabetes mellitus.
| Excerpt | Relevance | Reference |
|---|---|---|
| " There was a lower incidence of symptomatic hypoglycemia adverse events (AEs) with sitagliptin versus glipizide (6." | 2.78 | Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. ( Arjona Ferreira, JC; Barzilai, N; Goldstein, BJ; Golm, GT; Guo, H; Kaufman, KD; Marre, M; Sisk, CM, 2013) |
| "Glipizide treatment was initiated at 2." | 2.73 | Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. ( Amatruda, JM; Arjona Ferreira, JC; Chan, JC; Davies, MJ; Gonzalez, E; Kaufman, KD; Scott, R; Sheng, D; Stein, PP; Williams-Herman, D, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, JC | 1 |
| Scott, R | 1 |
| Arjona Ferreira, JC | 2 |
| Sheng, D | 1 |
| Gonzalez, E | 1 |
| Davies, MJ | 1 |
| Stein, PP | 1 |
| Kaufman, KD | 2 |
| Amatruda, JM | 1 |
| Williams-Herman, D | 1 |
| Marre, M | 1 |
| Barzilai, N | 1 |
| Guo, H | 1 |
| Golm, GT | 1 |
| Sisk, CM | 1 |
| Goldstein, BJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sitagliptin Study in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency[NCT00095056] | Phase 3 | 91 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Inadequate Glycemic Control[NCT00509262] | Phase 3 | 426 participants (Actual) | Interventional | 2007-10-09 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Safety and tolerability were measured in terms of the number of patients with clinical adverse experiences (CAEs), serious CAEs, drug-related CAEs, laboratory adverse experiences (LAEs), serious LAEs, and drug-related LAEs. Drug-relationship was assessed by the study investigator according to his/her best clinical judgment. (NCT00095056)
Timeframe: Week 0 through Week 12
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| With CAEs | With drug-related CAEs | With serious CAEs | With LAEs | With drug-related LAEs | With serious LAEs | |
| Placebo | 16 | 1 | 1 | 5 | 0 | 0 |
| Sitagliptin | 41 | 8 | 9 | 9 | 1 | 0 |
Safety and tolerability were measured in terms of the number of patients with clinical adverse experiences (CAEs), serious CAEs, drug-related CAEs, laboratory adverse experiences (LAEs), serious LAEs, and drug-related LAEs. Drug-relationship was assessed by the study investigator according to his/her best clinical judgment. (NCT00095056)
Timeframe: Week 0 through Week 54
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| With CAEs | With drug-related CAEs | With serious CAEs | With LAEs | With drug-related LAEs | With serious LAEs | |
| Placebo | 22 | 5 | 10 | 8 | 0 | 0 |
| Sitagliptin | 50 | 8 | 20 | 15 | 2 | 0 |
(NCT00509262)
Timeframe: Baseline to Week 54
| Intervention | kg (Least Squares Mean) |
|---|---|
| Sitagliptin | -0.6 |
| Glipizide | 1.2 |
Percentage of participants with at least one symptomatic hypoglycemic adverse event, excluding data after initiation of glycemic rescue therapy. (NCT00509262)
Timeframe: Baseline up to 28 days following the last dose of study therapy
| Intervention | percentage of participants (Number) |
|---|---|
| Sitagliptin | 6.2 |
| Glipizide | 17.0 |
(NCT00509262)
Timeframe: Baseline to Week 54
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Week 54 | |
| Glipizide | 143.9 | -20.2 |
| Sitagliptin | 148.6 | -16.7 |
A1C represents percentage of glycosylated hemoglobin. (NCT00509262)
Timeframe: Baseline to Week 54
| Intervention | Percent of glycosylated hemoglobin (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Week 54 | |
| Glipizide | 7.79 | -0.62 |
| Sitagliptin | 7.76 | -0.70 |
2 trials available for glipizide and Chronic Kidney Diseases
| Article | Year |
|---|---|
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency.
Topics: Aged; Blood Glucose; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Dose-Response Rela | 2008 |
Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency.
Topics: Body Weight; Diabetes Mellitus, Type 2; Female; Glipizide; Humans; Hypoglycemic Agents; Male; Pyrazi | 2013 |